Robert F. Friel
CIK: 0001224110
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)4 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- May 14, 2026XYL
Xylem Inc.
Award(A)Direct2.5K shares at avg. $116.88$290K - May 4, 2026WST
WEST PHARMACEUTICAL SERVICES INC
Award(A)Direct791 shares- - May 13, 2025XYL
Xylem Inc.
Award(A)Direct1.9K shares at avg. $126.93$235K - May 6, 2025WST
WEST PHARMACEUTICAL SERVICES INC
Award(A)Direct1.1K shares-
1-4 of 4 transactions
About FRIEL ROBERT F
FRIEL ROBERT F (SEC CIK 0001224110) files insider reports with the SEC as Director of Xylem Inc. (XYL) and Director of WEST PHARMACEUTICAL SERVICES INC (WST).
Signal8 holds 4 ownership filings by FRIEL ROBERT F, all Form 4s, filed between May 8, 2025 and May 15, 2026. Those filings report 4 transactions, from May 6, 2025 to May 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on FRIEL ROBERT F's filings is in EXTON, PA.
Recent filings by FRIEL ROBERT F
Other insiders filing for Xylem Inc. (XYL)
- KOCH D CHRISTIAN, Director
- Emmerich Meredith, EVP & President, MCS
- McShane Geri-Michelle, SVP, CAO
- van der Berg Andrea Michele, EVP & Chief Financial Officer
- Johnston Joseph Patrick, EVP & President, AW
- Grogan William K, EVP & Chief Financial Officer